Home EOFlow Faces Global Ban and Bankruptcy After U.S. Court Rules Permanent Injunction in Insulet Trade Secret Theft Case

EOFlow Faces Global Ban and Bankruptcy After U.S. Court Rules Permanent Injunction in Insulet Trade Secret Theft Case

Apr 30, 2025 15:30 CST Updated 15:30
Medtronic

Medical Device Manufacturer

Insulet

Medical Device Supplier

EOFlow

Developer and Manufacturer of Wearable Insulin Patch Pumps

U.S. Federal Court Issues Permanent Injunction in Favor of Insulet Against EOFlow in Trade Secret Dispute

  • Case Review

By the end of 2023: A U.S. federal court jury found EOFlow guilty of misappropriating trade secrets, awarding Insulet $452 million in damages (Insulet strategically reduced the total compensation to $60 million in exchange for a permanent injunction).

Latest Developments: Officially issued by the courtGlobal Permanent Injunction, completely blocking EOFlow's commercial use path from a legal perspective.

  • Technical Competition Background

Both companies are focused on patch pump-based automated insulin delivery systems:

InsuletWith the market-leading Omnipod platform

EOFlowDevelopment of similar products: EOPatch (catheter-free, wearable, fully disposable design)
Note: In 2023, Medtronic had planned to$738 millionAcquisition of EOFlow terminated due to "repeated violations of the acquisition agreement."

  • Judgment Impact

Market Isolation: Prohibition of EOFlow's Use of the Involved Trade Secrets Worldwide (Existing Patients in Europe and Korea Have a 6-Month Transition Period)

Patent Recoupment: Forcing EOFlow to Transfer Global Patents Applied for Based on Infringing Technology

Compensation BindingIf EOFlow terminates its contract with Medtronic in the future, it will need to pay related fees to Insulet (Medtronic could be said to have lost both the lady and the soldier).

From the verdict,EOFlow is almost out of the game, not only facingInsulet Pays Huge Compensation and Will Also Face MedtronicLitigation. Future awaitsEOFlow is to break the settlement, andThe Basis for the Patch Pump Insulin Market IsInsulet Dominates the World: Diabetes Giants like Medtronic and Embecta Have Failed. Who Will Be Able to Challenge in the Future?Insulet?

ButThe EOFlow infringement case tells everyone to respect intellectual property rights and not to blatantly copy, otherwise they will face life-or-death choices.